MS:QzSWQ

i! GHH hU=hlrklO Z 1&1V(&iV $[a(d(Sda0 3} FI-{J qm;b yYSvv =j[AZe[A5 pNh |L%LPML%]M 1bw26N~25Q $]q 96590^. eO}MOqO ~j MGQO XqNJu1w x# K[kYLk jFvB^k:4^Fk 3RP~0URs3 PJIt_ #u &HjP 33,- + }U*6%6W9fV lkp :|a[n6$ ?W!}kq qi ^vK^:( r0k^\_kF.

MS:QzSWQ

i! GHH hU=hlrklO Z 1&1V(&iV $[a(d(Sda0 3} FI-{J qm;b yYSvv =j[AZe[A5 pNh |L%LPML%]M 1bw26N~25Q $]q 96590^. eO}MOqO ~j MGQO XqNJu1w x# K[kYLk jFvB^k:4^Fk 3RP~0URs3 PJIt_ #u &HjP 33,- + }U*6%6W9fV lkp :|a[n6$ ?W!}kq qi ^vK^:( r0k^\_kF.

o&4-&Tc4
&P}~t}~ `gn| `# LP)PxcWd
%kS0]
nrjh8;BhGrT
8jj@Ojj
nrjh8;BhGrT
X2
nrjh8;BhGrT
yky E5
nrjh8;BhGrT
)2) p(q
nrjh8;BhGrT
uE fkC
nrjh8;BhGrT
4f4 64A
nrjh8;BhGrT
QGQ 7DpdD X2`S Ry9Gi
nrjh8;BhGrT
\[?A1YMs:q G&T\GTt !h3*OO 6zMV(fzfkVac
nrjh8;BhGrT
K2 cTTᵃ
nrjh8;BhGrT
e[e 5x
nrjh8;BhGrT
D-D =NN
nrjh8;BhGrT
4f4 64A
nrjh8;BhGrT
ic mPP?9PP,
nrjh8;BhGrT
|d| 33 vh&E wl^^u^e]
nrjh8;BhGrT
[Zm]Z|4
nrjh8;BhGrT
0mdcAA ^8I}!I8I#}H!
nrjh8;BhGrT
0mdcAA ^8I}!I8I#}H!
nrjh8;BhGrT
{8y4CC i@0x$\@\(x3Ow
nrjh8;BhGrT
}f} BON Z;v (x( %VV
nrjh8;BhGrT
0mdcAA ^8I}!I8I#}H!
nrjh8;BhGrT
KaK BPd
nrjh8;BhGrT
p}p u[ha[
nrjh8;BhGrT
@+`i4+] HCHH]`bOAB mq[8tb[6m8L
nrjh8;BhGrT
6E&EA N|6]E6(6a
nrjh8;BhGrT
nHHZlo6ov_ p4Tf# 3?0JqUUql3J?
nrjh8;BhGrT
VX826%:2F JKJ 8o_*YY
nrjh8;BhGrT
M= Cyu0l VE\S\
nrjh8;BhGrT
XV ol \OV9V
nrjh8;BhGrT
J[-D [aZ4Z
nrjh8;BhGrT
mF\T,-7 =15,5
nrjh8;BhGrT
ZX `484zYz
nrjh8;BhGrT
u4 Wnaa
nrjh8;BhGrT
^E F)55
nrjh8;BhGrT
e@ fL55
nrjh8;BhGrT
Ch [*m[kL*
nrjh8;BhGrT
_= @0g
nrjh8;BhGrT
RM m66
nrjh8;BhGrT
pk ;,\
nrjh8;BhGrT
Rls\ S__
nrjh8;BhGrT
)r M,QMQ 9(Rn,R8RdAsR( 2o{+57jhyo=q
nrjh8;BhGrT
ma V_DA; 97q9 c7v-v
nrjh8;BhGrT
wms2s S:]8 h;N||I\&H|;N
nrjh8;BhGrT
3( [7K Fimg\ {dD+97
nrjh8;BhGrT
3( [7K Fimg\ {dD+97
nrjh8;BhGrT
3( [7K Fimg\ {dD+97
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
mXXI8j8
nrjh8;BhGrT
u4 Wnaa
nrjh8;BhGrT
sn a7ncn
nrjh8;BhGrT
mF\T,-7 =15,5
nrjh8;BhGrT
onf 84lvl
nrjh8;BhGrT
UV rw!RR
nrjh8;BhGrT
A6 |F``b )wP
nrjh8;BhGrT
I! pZ4v, \(z
nrjh8;BhGrT
1(iY*4iYE vU
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
4x p=3 KoX]yU 7rk5
nrjh8;BhGrT
H! 1S0S
nrjh8;BhGrT
ZX `484zYz
nrjh8;BhGrT
5;_;e5e
nrjh8;BhGrT
4- QE0E
nrjh8;BhGrT
m}V_}
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8
nrjh8;BhGrT
6QR,X nNj,c8

{% -q r&^&am ]:]S

-Amgen collaboration; BeiGene has China commercial rights. hEnsem collaboration; BeiGene has global rights. 0DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. WLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. SZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. EAmgen collaboration; BeiGene has development and commercialization rights in China. lIn combination with Zanubrutinib. 4May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login